Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 626 - 628 of 628 in total

Olcegepant

Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational

Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate

Experimental

Ozarelix

Ozarelix has been used in trials studying the treatment of Prostate Cancer, Benign Prostatic Hypertrophy, and Benign Prostatic Hyperplasia (BPH).
Investigational
Displaying drugs 626 - 628 of 628 in total